Thirst
For Life

SYLVANT^® is currently licensed in EU, US and other countries worldwide including Australia, Canada, China, Mexico, South Korea and UK. SYLVANT^® is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

QARZIBA^® is currently licensed in the China, EU and other countries worldwide including Australia, Brazil, Israel, Hong Kong, Taiwan and UK. QARZIBA^® is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, QARZIBA^® should be combined with interleukin-2 (IL-2).*

*This is the EMA label indication. Please note that the label for this product may differ in other countries where dinutuximab beta is licensed. 

FOTIVDA^® is currently licensed in the EU, New Zealand, South Africa and UK. FOTIVDA^® is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

CAPHOSOL^® is licensed in China, EU, UK, US and other countries worldwide. It is approved for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). CAPHOSOL^® is available as ampules or in dispersible form.